PL3319969T3 - Diarylowe polimorfy makrocykliczne - Google Patents

Diarylowe polimorfy makrocykliczne

Info

Publication number
PL3319969T3
PL3319969T3 PL16821872.5T PL16821872T PL3319969T3 PL 3319969 T3 PL3319969 T3 PL 3319969T3 PL 16821872 T PL16821872 T PL 16821872T PL 3319969 T3 PL3319969 T3 PL 3319969T3
Authority
PL
Poland
Prior art keywords
polymorph
macrocycle
diaryl
diaryl macrocycle
macrocycle polymorph
Prior art date
Application number
PL16821872.5T
Other languages
English (en)
Inventor
Jingrong J. Cui
Evan W. ROGERS
Original Assignee
Turning Point Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics, Inc. filed Critical Turning Point Therapeutics, Inc.
Publication of PL3319969T3 publication Critical patent/PL3319969T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
PL16821872.5T 2015-07-06 2016-07-05 Diarylowe polimorfy makrocykliczne PL3319969T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188846P 2015-07-06 2015-07-06
US201562218672P 2015-09-15 2015-09-15
PCT/US2016/040972 WO2017007759A1 (en) 2015-07-06 2016-07-05 Diaryl macrocycle polymorph

Publications (1)

Publication Number Publication Date
PL3319969T3 true PL3319969T3 (pl) 2024-06-24

Family

ID=57685592

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16821872.5T PL3319969T3 (pl) 2015-07-06 2016-07-05 Diarylowe polimorfy makrocykliczne

Country Status (24)

Country Link
US (5) US10294242B2 (pl)
EP (2) EP3319969B1 (pl)
JP (2) JP6917974B2 (pl)
KR (1) KR102623734B1 (pl)
CN (2) CN108026108B (pl)
AU (1) AU2016289454B2 (pl)
BR (1) BR112018000297A2 (pl)
CA (1) CA2990020C (pl)
DK (1) DK3319969T3 (pl)
ES (1) ES2979111T3 (pl)
FI (1) FI3319969T3 (pl)
HR (1) HRP20240780T1 (pl)
HU (1) HUE067352T2 (pl)
IL (2) IL256443B (pl)
LT (1) LT3319969T (pl)
MX (2) MX386680B (pl)
PL (1) PL3319969T3 (pl)
PT (1) PT3319969T (pl)
RS (1) RS65593B1 (pl)
RU (1) RU2765181C2 (pl)
SI (1) SI3319969T1 (pl)
SM (1) SMT202400213T1 (pl)
WO (1) WO2017007759A1 (pl)
ZA (1) ZA201708436B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015209239C1 (en) 2014-01-24 2026-05-07 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
MX2017017097A (es) 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
PL3319969T3 (pl) * 2015-07-06 2024-06-24 Turning Point Therapeutics, Inc. Diarylowe polimorfy makrocykliczne
LT3733187T (lt) * 2015-07-21 2024-12-10 Turning Point Therapeutics, Inc. Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技(苏州)有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
CA3069232A1 (en) 2017-07-28 2019-01-31 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
HUE060711T2 (hu) 2017-12-19 2023-04-28 Turning Point Therapeutics Inc Makrociklusos vegyületek betegségek kezelésére
CN110386944B (zh) * 2018-04-16 2021-10-29 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
HRP20250048T1 (hr) 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba
WO2020233645A1 (zh) 2019-05-21 2020-11-26 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
US20220411439A1 (en) * 2019-06-19 2022-12-29 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
TW202133856A (zh) * 2019-11-27 2021-09-16 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JP7670711B2 (ja) * 2019-11-27 2025-04-30 ターニング・ポイント・セラピューティクス・インコーポレイテッド ジアリール大環状化合物を含む併用療法
BR112022017425A2 (pt) * 2020-03-02 2022-11-29 Turning Point Therapeutics Inc Usos terapêuticos de compostos macrocíclicos
CN113620974B (zh) * 2020-05-08 2023-01-31 山东轩竹医药科技有限公司 大环类酪氨酸激酶抑制剂的晶型及其制备方法
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法
WO2025217347A2 (en) 2024-04-11 2025-10-16 Bristol-Myers Squibb Company Process of preparing repotrectinib

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
DE3861031D1 (de) 1987-03-07 1990-12-20 Bayer Ag Verfahren zur herstellung von 5-amino-4,6-dihalogenpyridinen.
DK0690843T3 (da) 1993-03-25 2000-11-13 Upjohn Co Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet
PL182124B1 (pl) 1993-12-07 2001-11-30 Lilly Co Eli Nowe zwiazki oraz srodek farmaceutyczny przeznaczony do leczenia powiklan cukrzycowych lub do leczenia nowotworów PL PL PL PL PL PL PL PL
GB9403639D0 (en) 1994-02-25 1994-04-13 Boots Co Plc Therapeutic agents
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
DE60113865T2 (de) 2000-07-31 2006-07-20 Vernalis Research Ltd., Winnersh Piperazin derivate
DE60112611T2 (de) 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
WO2003011222A2 (en) * 2001-07-27 2003-02-13 Merck & Co., Inc. Thrombin inhibitors
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US8005919B2 (en) 2002-11-18 2011-08-23 Aol Inc. Host-based intelligent results related to a character stream
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
CN101128192A (zh) * 2005-01-10 2008-02-20 艾尼纳制药公司 用于治疗糖尿病和其相关病状以及用于治疗通过增加血液glp-1水平而改善的病状的组合疗法
US8960547B2 (en) 2007-09-19 2015-02-24 E-Seek, Inc. Document scanner with instant retrieval process
US8270176B2 (en) 2008-08-08 2012-09-18 Stats Chippac Ltd. Exposed interconnect for a package on package system
TWM352384U (en) 2008-08-22 2009-03-11 Luff Technology Co Ltd Wireless detection device for club and system thereof
CA2735420C (en) * 2008-09-08 2016-06-28 Merck Patent Gmbh Macrocyclic pyrimidines as protein kinase inhibitors
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
HRP20140309T1 (hr) 2008-10-22 2014-05-09 Array Biopharma, Inc. SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
JP5624148B2 (ja) 2009-10-13 2014-11-12 エランコ・アニマル・ヘルス・アイルランド・リミテッド 大環状インテグラーゼ阻害剤
WO2011071725A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
WO2011071716A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
KR102015402B1 (ko) * 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
GB2482674B (en) 2010-08-09 2012-08-22 Rolls Royce Plc An aerofoil, an aerofoil sub-assembly and a method of making the same
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2541470B1 (en) 2011-06-29 2017-10-04 Denso Wave Incorporated Information code and information code reader
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003798A2 (pt) * 2011-08-19 2017-03-01 Merck Sharp & Dohme método para fabricar um composto, e, composto
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
WO2013132376A1 (en) 2012-03-06 2013-09-12 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
NZ630719A (en) * 2012-03-09 2017-01-27 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
IN2014DN07384A (pl) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
ES2634014T3 (es) 2013-01-30 2017-09-26 Bayer Pharma Aktiengesellschaft Isotiazoles sustituidos con amino
CN105358534A (zh) 2013-04-23 2016-02-24 斯洛文尼亚莱柯制药股份有限公司 8-氯-1-甲基-苯并[d]吖庚因的新合成方法、新的中间体及其生产方法
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
US10497029B2 (en) * 2013-10-21 2019-12-03 Disney Enterprises, Inc. Systems and methods for facilitating brand integration within online content and promoting that online content
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AU2015209239C1 (en) 2014-01-24 2026-05-07 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
BR202014004079U2 (pt) 2014-02-21 2015-10-27 Mix For You Ltda higienizador íntimo
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
ES2983908T3 (es) 2014-12-15 2024-10-28 Cmg Pharmaceutical Co Ltd Compuestos heteroarílicos de anillo condensado y su uso como inhibidores de TRK
CN107531666A (zh) 2015-02-20 2018-01-02 里格尔药品股份有限公司 Gdf‑8抑制剂
WO2016143189A1 (ja) 2015-03-09 2016-09-15 住友ゴム工業株式会社 タイヤ
WO2016144846A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
MX2017014222A (es) 2015-05-05 2018-08-15 Bayer Pharma AG Derivados de ciclohexano sustituido con amido.
MX2017017097A (es) 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
US9524416B1 (en) 2015-07-03 2016-12-20 Fingerprint Cards Ab Fingerprint sensing device comprising three-dimensional pattern
PL3319969T3 (pl) * 2015-07-06 2024-06-24 Turning Point Therapeutics, Inc. Diarylowe polimorfy makrocykliczne
US10239565B2 (en) 2015-07-17 2019-03-26 John Michael Baker Pickup truck tailgate lifting apparatus
LT3733187T (lt) 2015-07-21 2024-12-10 Turning Point Therapeutics, Inc. Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP6580495B2 (ja) 2016-02-02 2019-09-25 三菱重工業株式会社 保持治具
AU2017228385B2 (en) 2016-03-04 2021-11-04 Vanderbilt University Substituted indole Mcl-1 inhibitors
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
US11384150B2 (en) 2016-12-14 2022-07-12 Development Center For Biotechnology Antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
WO2017007759A1 (en) 2017-01-12
US10294242B2 (en) 2019-05-21
CN113354653B (zh) 2024-12-31
HK1254492A1 (zh) 2019-07-19
US20250223298A1 (en) 2025-07-10
RS65593B1 (sr) 2024-06-28
MX386680B (es) 2025-03-19
BR112018000297A2 (pt) 2018-09-04
PT3319969T (pt) 2024-06-17
US20230295184A1 (en) 2023-09-21
IL283184A (en) 2021-06-30
EP3319969A1 (en) 2018-05-16
RU2018104269A3 (pl) 2019-12-17
KR102623734B1 (ko) 2024-01-10
ES2979111T3 (es) 2024-09-24
MX2021008145A (es) 2021-08-11
IL283184B2 (en) 2023-06-01
RU2018104269A (ru) 2019-08-06
MX2017017081A (es) 2018-08-16
SMT202400213T1 (it) 2024-07-09
US20180194777A1 (en) 2018-07-12
AU2016289454B2 (en) 2020-07-09
US20210094974A1 (en) 2021-04-01
ZA201708436B (en) 2021-03-31
CN108026108B (zh) 2021-06-22
LT3319969T (lt) 2024-06-10
AU2016289454A1 (en) 2018-01-04
EP4397665A3 (en) 2024-08-21
US12187739B2 (en) 2025-01-07
RU2765181C2 (ru) 2022-01-26
HRP20240780T1 (hr) 2024-09-13
CA2990020C (en) 2024-02-27
JP2021119151A (ja) 2021-08-12
IL256443A (en) 2018-02-28
KR20180026480A (ko) 2018-03-12
NZ738180A (en) 2024-04-26
SI3319969T1 (sl) 2024-09-30
CN113354653A (zh) 2021-09-07
US20190233437A1 (en) 2019-08-01
JP6917974B2 (ja) 2021-08-11
EP3319969A4 (en) 2019-07-03
HUE067352T2 (hu) 2024-10-28
EP3319969B1 (en) 2024-04-03
EP4397665A2 (en) 2024-07-10
DK3319969T3 (da) 2024-07-08
JP7212713B2 (ja) 2023-01-25
JP2018529633A (ja) 2018-10-11
CN108026108A (zh) 2018-05-11
CA2990020A1 (en) 2017-01-12
FI3319969T3 (fi) 2024-06-13
IL256443B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
ZA201708436B (en) Diaryl macrocycle polymorph
GB201510019D0 (en) Compounds
GB201514754D0 (en) Compounds
GB201508747D0 (en) Compounds
GB201514751D0 (en) Compounds
PL3362444T3 (pl) Związki
GB201520500D0 (en) Compounds
GB201520419D0 (en) Compounds
GB201520499D0 (en) Compounds
GB201510493D0 (en) Compounds
ZA201706005B (en) Diaza-benzofluoranthrene compounds
PT3331885T (pt) Compostos
GB201521682D0 (en) Compounds
GB201503926D0 (en) Compounds
GB201508857D0 (en) Compounds
GB201522246D0 (en) Compounds
GB201521440D0 (en) Compounds
GB201521086D0 (en) Compounds
GB201519965D0 (en) Compounds
GB201519969D0 (en) Compounds
GB201519212D0 (en) Compounds
GB201519213D0 (en) Compounds
GB201516445D0 (en) Compounds
GB201516059D0 (en) Compounds
GB201512279D0 (en) Compounds